AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — JP Morgan Healthcare Conference 2013

32 slides from AMAG Pharmaceuticals's conference presentation, Jan 7, 2013

  1. Slide 1: AMAG Pharmaceuticals JP Morgan Healthcare Conference January 2013

    Slide 1: AMAG Pharmaceuticals JP Morgan Healthcare Conference January 2013

    AMAG PHARMACEUTICALS JP Morgan Healthcare Conference January 2013

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to: (i) our

  3. Slide 3: AMAG: 2012 Highlights

    Slide 3: AMAG: 2012 Highlights

    AMAG: 2012 HIGHLIGHTS Continued growth of Feraheme U.S. CKD business Drove 17% Feraheme volume growth in the US compared to 2011 Exited year with 14% market share in grams Improved net revenue per gram for Feraheme Significant progress in Feraheme expansion efforts Completed phase III program for br

  4. Slide 4: Marketed Product Feraheme (ferumoxytol) Injection

    Slide 4: Marketed Product Feraheme (ferumoxytol) Injection

    Marketed Product Feraheme® (ferumoxytol) Injection for intravenous (IV) use, an IV iron replacement therapy Approved in the U.S., Europe, Switzerland and Canada Indicated for adult patients with chronic kidney disease (CKD) with iron deficiency anemia (IDA) 3 Orange Book listed patents; 2020 expiry;

  5. Slide 5: Leveraging Our Assets and Core Competencies to Build a Multi-Product Specialty Pharmaceutical Company

    Slide 5: Leveraging Our Assets and Core Competencies to Build a Multi-Product Specialty Pharmaceutical Company

    AMAG: LEVERAGING OUR ASSETS AND CORE COMPETENCIES TO BUILD A PROFITABLE, MULTI-PRODUCT SPECIALTY PHARMACEUTICAL COMPANY Commercial Infrastructure Focus on Hematology/Oncology, Hospital and Nephrology Strong Balance Sheet Product #2 Product #3 Experienced Management Team Feraheme U.S. CKD Business Fe

  6. Slide 6: U.S. IV Iron Market

    Slide 6: U.S. IV Iron Market

    | U.S. IV IRON MARKET

  7. Slide 7: Current US Non-Dialysis IV Iron Market ~$400 Million

    Slide 7: Current US Non-Dialysis IV Iron Market ~$400 Million

    CURRENT US NON-DIALYSIS IV IRON MARKET ~ $400 MILLION (FERAHEME DOLLARS) 50% of market is for treatment of patients with CKD Primary sites of treatment are hematology / oncology clinics and hospitals ~70% of market reimbursed at ASP+ model 7

  8. Slide 8: U.S. Non-Dialysis CKD IV Iron Market Opportunity

    Slide 8: U.S. Non-Dialysis CKD IV Iron Market Opportunity

    U.S. NON-DIALYSIS CKD IV IRON MARKET OPPORTUNITY Current Feraheme Opportunity Expanded Label Opportunity (sNDA submitted December 2012) Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Natio

  9. Slide 9: Feraheme Performance in the U.S.

    Slide 9: Feraheme Performance in the U.S.

    FERAHEME PERFORMANCE IN THE U.S.

  10. Slide 10: About Feraheme (ferumoxytol)/Rienso

    Slide 10: About Feraheme (ferumoxytol)/Rienso

    ABOUT FERAHEME® (FERUMOXYTOL)/RIENSO In the United States, Feraheme (ferumoxytol) Injection for Intravenous (IV) use is indicated for the treatment of iron deficiency anemia in adult chronic kidney disease (CKD) patients. Feraheme received marketing approval from the U.S. Food and Drug Administratio

  11. Slide 11: Non-Dialysis Market Share Shift Since Feraheme Launch

    Slide 11: Non-Dialysis Market Share Shift Since Feraheme Launch

    NON-DIALYSIS MARKET SHARE SHIFT SINCE FERAHEME LAUNCH (ASP DOLLARS) 11 ® ® ® ® Demand information is based on data from IMS Health; market share is calculated on published ASP data.

  12. Slide 12: IV Iron Historical Dosing Paradigm

    Slide 12: IV Iron Historical Dosing Paradigm

    IV IRON HISTORICAL DOSING PARADIGM One gram of IV iron is the usual therapeutic course. Labels of Venofer and Ferrlecit were harmonized by the FDA in the summer of 2011 to all include post-dose observation periods and similar language regarding hypersensitivity reactions in the warnings and precauti

  13. Slide 13: Feraheme Is As Easy As 1 Gram, 2 Doses, 3-8 Days Apart

    Slide 13: Feraheme Is As Easy As 1 Gram, 2 Doses, 3-8 Days Apart

    FERAHEME IS AS EASY AS 1 – 2 – 3 1 GRAM, 2 DOSES, 3 DAYS APART One gram of IV iron is the usual therapeutic course and that which was studied in the Feraheme clinical trials. Feraheme Indication and contraindications Feraheme ® (ferumoxytol) Injection for Intravenous (IV) is indicated for the treatm

  14. Slide 14: 2012 – Strong Growth in Feraheme Provider Demand

    Slide 14: 2012 – Strong Growth in Feraheme Provider Demand

    2012 – STRONG GROWTH IN FERAHEME PROVIDER DEMAND 14 Source: IMS Health Data. 17% Grams 2012 Results 17% increase in Feraheme provider demand; 115 evolution index 4th Quarter Share 14% of non-dialysis IV iron market 26% of heme/onc segment 9% of hospital segment 34% of nephrology segment

  15. Slide 15: Expansion Opportunities

    Slide 15: Expansion Opportunities

    | EXPANSION OPPORTUNITIES avn’

  16. Slide 16: U.S. Broad IDA IV Iron Market Opportunity Today

    Slide 16: U.S. Broad IDA IV Iron Market Opportunity Today

    U.S. BROAD IDA IV IRON MARKET OPPORTUNITY TODAY Current Feraheme Opportunity Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes an

  17. Slide 17: U.S. Broad IDA IV Iron Market Opportunity Today

    Slide 17: U.S. Broad IDA IV Iron Market Opportunity Today

    U.S. BROAD IDA IV IRON MARKET OPPORTUNITY TODAY Current Feraheme Opportunity Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes an

  18. Slide 18: Broad IDA Label Expansion Plans

    Slide 18: Broad IDA Label Expansion Plans

    BROAD IDA LABEL EXPANSION PLANS 18 2012 2013 2014 sNDA submitted to FDA Global 1,400 patient phase III program completed Potential U.S. sNDA approval IDA submission in EU Potential IDA approval in EU (milestone to AMAG)

  19. Slide 19: IDA-301: Patient Reported Outcomes of Ferumoxytol-Treated Patients

    Slide 19: IDA-301: Patient Reported Outcomes of Ferumoxytol-Treated Patients

    IDA-301: PATIENT REPORTED OUTCOMES OF 600 FERUMOXYTOL-TREATED PATIENTS 19 In IDA-301, clinically meaningful improvements in multiple patient-reported outcome instruments were associated with increases in hemoglobin; no new safety signals were observed in the study. 48% 59% 28% 33% Primary Endpoint S

  20. Slide 20: IV Iron Market Expansion Opportunity

    Slide 20: IV Iron Market Expansion Opportunity

    IV IRON MARKET EXPANSION OPPORTUNITY 20 Expansion Opportunity Current IV Iron Market

  21. Slide 21: Gastroenterology – A Prime Opportunity Upon Approval

    Slide 21: Gastroenterology – A Prime Opportunity Upon Approval

    GASTROENTEROLOGY – A PRIME OPPORTUNITY UPON APPROVAL 21 Causes of IDA Chronic GI disorders Inflammatory bowel disease >150,000 with IDA Bleeds of unknown origin Malabsorption disorders Celiac disease Bariatric surgery patients >150,000 with IDA Cannot tolerate or absorb oral iron Chronically iron de

  22. Slide 22: AMAG's GI Pre-Launch Activities

    Slide 22: AMAG's GI Pre-Launch Activities

    AMAG’S GI PRE-LAUNCH ACTIVITIES Further understand view of anemia management Market research Advisory boards Meet with key opinion leaders in the treatment of IBD and bariatric surgeons who are thought leaders in IDA Meet with advocacy groups to understand the community Educate Present GI-specific d

  23. Slide 23: International Expansion Brings Near-Term Growth

    Slide 23: International Expansion Brings Near-Term Growth

    INTERNATIONAL EXPANSION BRINGS NEAR-TERM GROWTH Approved for CKD indication in Europe and Canada Launches began in 4Q12 and will continue through 2013 Deal terms $60 million upfront payment $33 million in milestone payments in 2012 related to ex-US approvals and launches $187 million in milestones r

  24. Slide 24: Future Annual Sales Opportunity

    Slide 24: Future Annual Sales Opportunity

    FUTURE ANNUAL SALES OPPORTUNITY 24

  25. Slide 25: Portfolio Expansion

    Slide 25: Portfolio Expansion

    PORTFOLIO EXPANSION Current focus Commercial product acquisitions Assets that can be purchased with AMAG’s existing cash Products with annual revenues of $10 million to $60 million Products with growth potential that leverage our commercial footprint Positive impact on Feraheme Strong intellectual p

  26. Slide 26: Financial Overview

    Slide 26: Financial Overview

    | FINANCIAL OVERVIEW

  27. Slide 27: 2012 Projected Financial Highlights

    Slide 27: 2012 Projected Financial Highlights

    2012 PROJECTED FINANCIAL HIGHLIGHTS ($ in millions) 4Q2012 Estimate 4Q2011 Change Total Revenues $21.1 – $21.5 $14.9 ~43% Net Feraheme U.S. Product Revenues $14.4 – $14.8 $12.8 ~14% Total Operating Expenses $21.0 – $22.5 $31.7 ~(31%) Cash and Investments $227 $230 ~(1%) 27 ($ in millions) 2012 Estim

  28. Slide 28: Improving Net Revenue per Gram of Feraheme Sold

    Slide 28: Improving Net Revenue per Gram of Feraheme Sold

    IMPROVING NET REVENUE PER GRAM OF FERAHAME SOLD 28 Realizing benefit of price increases taken in 2012 Reversed historically deteriorating net revenue per gram in 2012 ASP has increased in each of last two quarters * Net price per gram is calculated by deducting estimated fees, discounts, rebates, an

  29. Slide 29: AMAG: Cash Flow Trajectory

    Slide 29: AMAG: Cash Flow Trajectory

    AMAG: CASH FLOW TRAJECTORY 29 $ millions 2012 -$35 million (excluding milestones) 2013 -$18 million Illustrative IDA Investment 2014

  30. Slide 30: 2013 Financial Outlook

    Slide 30: 2013 Financial Outlook

    2013 FINANCIAL OUTLOOK 30 Expenses ($ in millions) Total Revenues of $73 - $77 million $63 – $67 million in Feraheme net U.S. product revenue Operating expenses of $78– $82 million (excluding COGS) R&D expenses decline New Investments for IDA launch COGS: 14%-18% of product sales End 2013 with $206

  31. Slide 31: Building Off a Base of Success in 2013

    Slide 31: Building Off a Base of Success in 2013

    BUILDING OFF A BASE OF SUCCESS IN 2013 31 Stabilized organization and turned focus to execution and growth Continued growth of Feraheme US CKD business Drove 17% Feraheme volume growth in the US Improved net revenue per gram for Feraheme Significant progress in Feraheme expansion efforts Completed p

  32. Slide 32: AMAG Pharmaceuticals: Well Positioned for Growth in 2013... and Beyond

    Slide 32: AMAG Pharmaceuticals: Well Positioned for Growth in 2013... and Beyond

    AMAG PHARMACEUTICALS Well positioned for growth in 2013... and beyond

Source: SEC EDGAR · 8-K filed Jan 7, 2013

More decks from AMAG Pharmaceuticals Inc